November 11, 2015 RESVERLOGIX COMMENCES DOSING IN PHASE 3 CLINICAL TRIAL BETONMACE

The first patients in BETonMACE who started dosing back on or around November 11, 2015 are reaching the end of the apabetalone or placebo treatment phase (104 weeks) and will begin entering into the 4-16 week safety follow up period (assuming of course that these patients are still alive and that the BETonMACE trial design shown on slide 16 of the Nov 7th, 2017 BIO-Europe presentation is still accurate). 

Happy 2 year Anniversary!

BearDownAZ